Garenoxacin Mesylate

CHEMBL3183451 Phase 4 Đã phê duyệt Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

540.5 g/mol

LogP

—

Phase

4

This mesylate salt form of garenoxacin is an oral fluoroquinolone antibiotic used primarily for community-acquired pneumonia and other respiratory infections. It has a broad spectrum of antibacterial activity including coverage of resistant respiratory pathogens.

Khối lượng phân tử

540,5000 g/mol

TPSA

143,00 Å²

Cơ chế tác dụng

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Cấu trúc 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CS(=O)(=O)O.C[C@H]1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21.O

InChI

InChI=1S/C23H20F2N2O4.CH4O3S.H2O/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30;1-5(2,3)4;/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30);1H3,(H,2,3,4);1H2/t11-;;/m1../s1

Molecular Formula

C24H26F2N2O8S

HBD / HBA

4 / 12

Liên kết có thể quay

5

Nguyên tử nặng

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This mesylate salt form of garenoxacin is an oral fluoroquinolone antibiotic used primarily for community-acquired pneumonia and other respiratory infections. It has a broad spectrum of antibacterial activity including coverage of resistant respiratory pathogens.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Garenoxacin Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3183451. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 157690. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Bạn đang tìm kiếm thông tin thân thiện với bệnh nhân?

Garenoxacin Mesylate trên PillFYI

Cấu trúc

Dữ liệu nhanh

Công thức: C24H26F2N2O8S

Liên kết ngoài

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Garenoxacin Mesylate

Cơ chế tác dụng

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Câu hỏi thường gặp

References & Data Sources

Embed This Widget